ClinicalTrials.gg
CompletedNCT02023112GIFT-IIUpdated Jul 30, 2021Results posted

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection

A Phase 3 interventional study of ABT-450/r/ABT-267 and Ribavirin in Hepatitis C Virus, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-30.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing paritaprevir in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. paritaprevir · Hepatitis C.

Enrollment
10th of 29
171 · median 99
Started
2014
with 1 other
Phase 3
14 of 29
none open now
Registered
17th of 29
by date
Lead sponsor
14 of 29
AbbVie

Among the 29 studies testing paritaprevir in Hepatitis C, this one is the 10th largest by enrollment, is one of 2 that started in 2014, is one of 14 in phase 3, and was the 17th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 29 studies testing paritaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About paritaprevir

paritaprevir: first FDA approval 2015 (TECHNIVIE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing paritaprevir in Hepatitis C as a file.
02

Study summary

This is a Phase 3, randomized, open-label, multicenter study, enrolling non-cirrhotic and cirrhotic subjects. The purpose of this study is to evaluate the efficacy and safety of ABT-450/r/ABT-267 co-administered with weight-based RBV for 12 or 16 weeks in adult chronic HCV genotype 2-infected treatment-naïve and interferon (IFN) treatment-experienced subjects with and without compensated cirrhosis.

03

Conditions studied

  • Hepatitis C Virus

Browse trials for

Keywords

  • Japanese
  • Hepatitis C
  • Treatment naive
  • Treatment experienced
  • Genotype 2
  • Ombitasvir
  • Paritaprevir
  • Ritonavir
  • Ribavirin
  • VIEKIRAX Combination Tablets
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic -infection prior to study enrollment
  • Screening laboratory result indicating HCV genotype 2 infection
  • Subject has plasma HCV ribonucleic acid (RNA) level greater than 10,000 IU/mL at Screening
  • Voluntarily sign an

Exclusion criteria

Exclusion Criteria:

  • Co-infection of Virus (HBV), (HIV) and any genotype other than genotype 2
  • Prior therapy with direct acting antiviral agents for the treatment of HCV, including telaprevir, simeprevir and boceprevir
  • Any cause of liver disease other than chronic HCV-infection, including but not limited to the following: hemochromatosis; alpha-1 antitrypsin deficiency; Wilson's disease; hepatitis; alcoholic liver disease; drug-related liver disease
  • laboratory abnormalities
  • Uncontrolled clinically significant disease, disorder or medical illness
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    ABT-450/r/ABT-267 plus RBV for 12 weeks

    ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based ribavirin (RBV; 400 to 1,000 mg/day, divided twice daily) for 12 weeks

    Drug: ABT-450/r/ABT-267 · Drug: Ribavirin

  • Experimental
    ABT-450/r/ABT-267 plus RBV for 16 weeks

    ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based RBV (400 to 1,000 mg/day, divided twice daily) for 16 weeks

    Drug: ABT-450/r/ABT-267 · Drug: Ribavirin

Interventions

  • DrugABT-450/r/ABT-267

    Drug pages: Paritaprevir · Ritonavir · Ombitasvir

    Tablet; ABT-450 coformulated with ritonavir and ABT-267

    Also known as: ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir also known as Norvir, VIEKIRAX Combination Tablets, VIEKIRA Combination Tablets, Technivie, Qurevo

  • Capsule

06

What researchers measure

Primary outcomes

  1. Percentage of Non-cirrhotic, Treatment-naive Participants in Each Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

    The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.

    Time frame: 12 weeks after last dose of study drug

Secondary outcomes

  1. Percentage of Participants in Each Treatment Arm With On-treatment Virologic Failure During the Treatment Period

    On-treatment virologic failure was defined as rebound (confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment, or confirmed increase from nadir in HCV RNA \[\> 1 log10 IU/mL above nadir\] at any time point during treatment) or failure to suppress HCV during treatment (all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment).

    Time frame: 12 or 16 weeks (end of treatment period)

  2. Percentage of Participants With Post-treatment Relapse

    Relapse by post-treatment Week 12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug for a participant with HCV RNA \< LLOQ at the final treatment visit and who completed study treatment. Completion of treatment was defined as a study drug duration ≥ 77 days for the 12-week treatment arm or ≥ 105 days for the 16-week treatment arm.

    Time frame: within 12 weeks after the last dose of study drug

  3. Percentage of Participants With SVR12 Weeks Post-treatment for Each Treatment Arm Within Different Subpopulations

    The percentage of participants with SVR12 in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; noncirrhotic participants who relapsed after prior IFN-based therapy (relapsers); noncirrhotic T-exp participants who were non-responders to prior IFN-based therapy; noncirrhotic T-exp participants who were intolerant to IFN-based therapy; participants with compensated cirrhosis.

    Time frame: 12 weeks after last dose of study drug

  4. Percentage of Participants in Each Treatment Arm With On-treatment Virologic Failure During the Treatment Period for Each Treatment Arm Within Different Subpopulations

    The percentage of participants with on-treatment virologic failure in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; participants with compensated cirrhosis. On-treatment virologic failure was defined as rebound (confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment, or confirmed increase from nadir in HCV RNA \[\> 1 log10 IU/mL above nadir\] at any time point during treatment) or failure to suppress HCV during treatment (all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment).

    Time frame: 12 or 16 weeks (end of treatment period)

  5. Percentage of Participants With Post-treatment Relapse Within Different Subpopulations

    The percentage of participants with relapse by post-treatment Week 12 in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; participants with compensated cirrhosis. Relapse by post-treatment Week 12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug for a participant with HCV RNA \< LLOQ at the final treatment visit and who completed study treatment. Completion of treatment was defined as a study drug duration ≥ 77 days for the 12-week treatment arm or ≥ 105 days for the 16-week treatment arm.

    Time frame: within 12 weeks after the last dose of study drug

07

Results

Posted May 13, 2016

Participant flow

Participant flow — Overall Study
MilestoneABT-450/r/ABT-267 Plus RBV for 12 WeeksABT-450/r/ABT-267 Plus RBV for 16 Weeks
Started8586
Completed8385
Not completed21
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryPercentage of Non-cirrhotic, Treatment-naive Participants in Each Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.

Time frame:
12 weeks after last dose of study drug
Reported as:
Number · percentage of participants
Percentage of Non-cirrhotic, Treatment-naive Participants in Each Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
percentage of participantsABT-450/r/ABT-267 Plus RBV for 12 WeeksABT-450/r/ABT-267 Plus RBV for 16 Weeks
Percentage of Non-cirrhotic, Treatment-naive Participants in Each Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment (SVR12)75.091.5
Statistical analysis
  • ABT-450/r/ABT-267 Plus RBV for 16 Weeks · Percentage of participants with svr12: 91.5 · 95% CI 80.1 to 96.6Tested using the following hierarchical order: among non-cirrhotic treatment-naïve participants 1) superiority of 16-week treatment arm to a clinically relevant threshold; 2) superiority of 12-week treatment arm to a clinically relevant threshold.
  • ABT-450/r/ABT-267 Plus RBV for 12 Weeks · Percentage of participants with svr12: 75.0 · 95% CI 61.2 to 85.1Tested using the following hierarchical order: among non-cirrhotic treatment-naïve participants 1) superiority of 16-week treatment arm to a clinically relevant threshold; 2) superiority of 12-week treatment arm to a clinically relevant threshold.
SecondaryPercentage of Participants in Each Treatment Arm With On-treatment Virologic Failure During the Treatment Period

On-treatment virologic failure was defined as rebound (confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment, or confirmed increase from nadir in HCV RNA \[\> 1 log10 IU/mL above nadir\] at any time point during treatment) or failure to suppress HCV during treatment (all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment).

Time frame:
12 or 16 weeks (end of treatment period)
Reported as:
Number · percentage of participants
Percentage of Participants in Each Treatment Arm With On-treatment Virologic Failure During the Treatment Period
percentage of participantsABT-450/r/ABT-267 Plus RBV for 12 WeeksABT-450/r/ABT-267 Plus RBV for 16 Weeks
Overall8.38.5
Rebound8.38.5
Failure to suppress00
SecondaryPercentage of Participants With Post-treatment Relapse

Relapse by post-treatment Week 12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug for a participant with HCV RNA \< LLOQ at the final treatment visit and who completed study treatment. Completion of treatment was defined as a study drug duration ≥ 77 days for the 12-week treatment arm or ≥ 105 days for the 16-week treatment arm.

Time frame:
within 12 weeks after the last dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Post-treatment Relapse
percentage of participantsABT-450/r/ABT-267 Plus RBV for 12 WeeksABT-450/r/ABT-267 Plus RBV for 16 Weeks
Percentage of Participants With Post-treatment Relapse12.20
SecondaryPercentage of Participants With SVR12 Weeks Post-treatment for Each Treatment Arm Within Different Subpopulations

The percentage of participants with SVR12 in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; noncirrhotic participants who relapsed after prior IFN-based therapy (relapsers); noncirrhotic T-exp participants who were non-responders to prior IFN-based therapy; noncirrhotic T-exp participants who were intolerant to IFN-based therapy; participants with compensated cirrhosis.

Time frame:
12 weeks after last dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With SVR12 Weeks Post-treatment for Each Treatment Arm Within Different Subpopulations
percentage of participantsABT-450/r/ABT-267 Plus RBV for 12 WeeksABT-450/r/ABT-267 Plus RBV for 16 Weeks
All participants; n=85, 8672.9 (62.7 to 81.2)81.4 (71.9 to 88.2)
Noncirrhotic participants; n=80, 8072.5 (61.9 to 81.1)85.0 (75.6 to 91.2)
Noncirrhotic T-exp; n=32, 3368.8 (51.4 to 82.0)75.8 (59.0 to 87.2)
Noncirrhotic T-exp Relapser; n=15, 1680.0 (54.8 to 93.0)93.8 (71.7 to 98.9)
Noncirrhotic T-exp Nonresponder; n=5, 640.0 (11.8 to 76.9)50.0 (18.8 to 81.2)
Noncirrhotic T-exp IFN-intolerant; n=12, 1166.7 (39.1 to 86.2)63.6 (35.4 to 84.8)
Cirrhotic Participants; n=5, 680.0 (37.6 to 96.4)33.3 (9.7 to 70.0)
SecondaryPercentage of Participants in Each Treatment Arm With On-treatment Virologic Failure During the Treatment Period for Each Treatment Arm Within Different Subpopulations

The percentage of participants with on-treatment virologic failure in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; participants with compensated cirrhosis. On-treatment virologic failure was defined as rebound (confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment, or confirmed increase from nadir in HCV RNA \[\> 1 log10 IU/mL above nadir\] at any time point during treatment) or failure to suppress HCV during treatment (all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment).

Time frame:
12 or 16 weeks (end of treatment period)
Reported as:
Number · percentage of participants
Percentage of Participants in Each Treatment Arm With On-treatment Virologic Failure During the Treatment Period for Each Treatment Arm Within Different Subpopulations
percentage of participantsABT-450/r/ABT-267 Plus RBV for 12 WeeksABT-450/r/ABT-267 Plus RBV for 16 Weeks
All Participants: Overall; n=85, 8615.316.3
All Participants: Rebound; n=85, 8615.315.1
All Participants: Failure to Suppress; n=85, 864.74.7
Noncirrhotic: Overall; n=80, 8015.013.8
Noncirrhotic: Rebound; n=80, 8015.012.5
Noncirrhotic: Failure to Suppress; n=80, 803.83.8
Noncirrhotic T-exp: Overall; n=32, 3325.021.2
Noncirrhotic T-exp: Rebound; n=32, 3325.018.2
Noncirrhotic T-exp: Failure to Suppress; n=32, 339.49.1
Cirrhotic: Overall; n=5, 620.050.0
Cirrhotic: Rebound; n=5, 620.050.0
Cirrhotic: Failure to Suppress; n=5, 620.016.7
SecondaryPercentage of Participants With Post-treatment Relapse Within Different Subpopulations

The percentage of participants with relapse by post-treatment Week 12 in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; participants with compensated cirrhosis. Relapse by post-treatment Week 12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug for a participant with HCV RNA \< LLOQ at the final treatment visit and who completed study treatment. Completion of treatment was defined as a study drug duration ≥ 77 days for the 12-week treatment arm or ≥ 105 days for the 16-week treatment arm.

Time frame:
within 12 weeks after the last dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Post-treatment Relapse Within Different Subpopulations
percentage of participantsABT-450/r/ABT-267 Plus RBV for 12 WeeksABT-450/r/ABT-267 Plus RBV for 16 Weeks
All Participants; n=69, 7010.10
Noncirrhotic Participants; n=65, 6810.80
Noncirrhotic T-exp Participants; n=24, 258.30
Cirrhotic Participants; n=4, 200

Adverse events

Collected over Non-serious adverse events collected from initiation of study drug through 30 days post-study drug dosing (12 weeks or 16 weeks, depending on arm assignment); serious adverse events collected from signing of Informed Consent up to Post-treatment Week 48.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABT-450/r/ABT-267 Plus RBV for 12 Weeks (Non-cirrhotic)—0/80 (0%)52/80 (65%)
ABT-450/r/ABT-267 Plus RBV for 16 Weeks (Non-cirrhotic)—3/80 (3.8%)53/80 (66.3%)
ABT-450/r/ABT-267 Plus RBV for 12 Weeks (Cirrhotic)—0/5 (0%)3/5 (60%)
ABT-450/r/ABT-267 Plus RBV for 16 Weeks (Cirrhotic)—0/6 (0%)4/6 (66.7%)
Most frequent serious events
Most frequent serious events
EventABT-450/r/ABT-267 Plus RBV for 12 Weeks (Non-cirrhotic)ABT-450/r/ABT-267 Plus RBV for 16 Weeks (Non-cirrhotic)ABT-450/r/ABT-267 Plus RBV for 12 Weeks (Cirrhotic)ABT-450/r/ABT-267 Plus RBV for 16 Weeks (Cirrhotic)
GASTRITIS ALCOHOLICGastrointestinal disorders0/801/800/50/6
BRONCHOPNEUMONIAInfections and infestations0/801/800/50/6
INCISIONAL HERNIAInjury, poisoning and procedural complications0/801/800/50/6
Most frequent other events
Showing 10 of 31
Most frequent other events
EventABT-450/r/ABT-267 Plus RBV for 12 Weeks (Non-cirrhotic)ABT-450/r/ABT-267 Plus RBV for 16 Weeks (Non-cirrhotic)ABT-450/r/ABT-267 Plus RBV for 12 Weeks (Cirrhotic)ABT-450/r/ABT-267 Plus RBV for 16 Weeks (Cirrhotic)
ANAEMIABlood and lymphatic system disorders16/8020/800/51/6
BLOOD BILIRUBIN INCREASEDInvestigations16/8014/800/51/6
HAEMOGLOBIN DECREASEDInvestigations6/804/801/50/6
HEADACHENervous system disorders11/806/801/50/6
HEAT ILLNESSInjury, poisoning and procedural complications0/800/801/50/6
BLOOD URIC ACID INCREASEDInvestigations0/800/801/50/6
PRURITUS GENERALISEDSkin and subcutaneous tissue disorders0/801/801/50/6
MUSCULOSKELETAL STIFFNESSMusculoskeletal and connective tissue disorders0/800/801/50/6
SOMNOLENCENervous system disorders0/800/801/50/6
POLLAKIURIARenal and urinary disorders0/800/801/50/6

Baseline characteristics

Age, Customized
Age, Customized(participants)ABT-450/r/ABT-267 Plus RBV for 12 WeeksABT-450/r/ABT-267 Plus RBV for 16 WeeksTotal
< 65 years5662118
≥ 65 years292453
Sex: Female, Male
Sex: Female, Male(Participants)ABT-450/r/ABT-267 Plus RBV for 12 WeeksABT-450/r/ABT-267 Plus RBV for 16 WeeksTotal
Female404888
Male453883
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Sato K, Chayama K, Alves K, Toyoda H, Suzuki F, Kato K, Rodrigues L Jr, Zhang X, Setze C, Pilot-Matias T, Burroughs M, Redman R, Kumada H. Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients. Adv Ther. 2017 Jun;34(6):1449-1465. doi: 10.1007/s12325-017-0506-y. Epub 2017 May 23. PubMed 28536999 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Apr 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2013
First posted
Dec 30, 2013
Start
Jan 2014
Primary completionActual
Apr 2015
CompletionActual
Sep 2015
Results first posted
May 13, 2016
Last update
Jul 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02023112
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 30, 2013
Start date
Jan 2014
Primary completion
Apr 2015
Completion
Sep 2015
Results posted
May 13, 2016
Last update
Jul 30, 2021

Study contacts

Yasunori Yachi
study director · AbbVie

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paritaprevir · Ritonavir · Ombitasvir · Ribavirin

Start the discussion